

Draft

**E.P.A.
Proposed Meeting***

I. Appreciation and Introductions

Dr. Charles (Chuck) Reich	Group Vice President	Chemical Markets Group
Dr. William (Bill) A. Weppner	Director EHS&R Affairs	Chemical Markets Group
Mr. Daniel (Dan) C. Hakes	Product Stewardship	Chemical Markets Group
Dr. Larry R. Zobel	Staff Vice President and Medical Director	3M

II. Purpose -

- A) Meeting to scope the issues surrounding the discovery of PFOS (perfluoro octane sulfonate) in blood samples from the general population. 8(E) filing in May, 1998.
- B) Brief you on present knowledge and current plans
Toxicology and human health data
Environmental fate and assessments
Regulatory actions
Exposure assessments and precautionary principle actions
Communications (product stewardship)
- C) Current View: 3M does not believe that any reasonable basis exists to conclude that PFOS "presents a substantial risk of injury to health or the environment". Nevertheless, gaps of knowledge do exist that must be addressed. We view this as a serious issue, but not an alarming issue.
- D) Future View: We are working under the precautionary principle to minimize the possibility for intake into humans and the environment from any chemicals that can be metabolic precursors, or become metabolic precursors of PFOS. Our goal is to work in a deliberate and purposeful way so as to move the eco-burden down over time to non-detectable levels. Our current exposure assessments and actions taken with regards to product, plant emissions, and product stewardship initiatives are already moving us in this direction.

REDACTED

**Exhibit
2719**

State of Minnesota v. 3M Co.,
Court File No. 27-CV-10-28862

3MA10071231

2719.0001

E) 3M Commitment

3M executive management is totally committed to this precautionary principle approach. We have forty teams dealing with the complex tasks surrounding this issue. Virtually 300 plus individuals are engaged to a significant amount of their time on this issue. Literally the rate of spend on just testing and enlisting outside professional help is in the tens of millions of dollars. All of the team activities are focused through a working group, the leader of which reports to me. In turn, as a Management Committee member and Corporate Officer, I review progress to a Corporate oversight committee.

F) Outside Professional Assistance

We have engaged numerous consultants to advise us on, as a partial list, toxicology, risk assessment, environment assessments, analytical procedures, communications, industrial hygiene, and occupational medicine. In addition, we have established an independent Scientific Advisory Panel to help guide our understanding of the health data, past and future.

G) Need for Cooperation

Today we are here to seek your input to this issue. We recognize your responsibility to formulate and administer health protection policies.

3M's responsibility is to provide products and services that offer realizable benefits and are safe for their intended use.

We see our goals as being mutually inclusive and the basis upon which together we can cooperate in managing this issue.

Conclusion

In summary, you can see that 3M is taking this issue very seriously. A great deal of data has been and will continue to be generated. We are acting upon that data. We are resolved in our determination to operate upon our precautionary principle of minimizing to non-measurable levels the presence of PFOS in humans and the environment.

We are committed to all aspects of the program we've reviewed for you.

We expect and welcome regular updates with the EPA on our results and we welcome feedback from the EPA on the scope of our efforts.

We seek the EPA's view on various structuring arrangements for cooperation going forward and specifically what the next steps may be.


C. Reich

*My section is all verbal. No visuals will be used.

REDACTED

